Long Covid Clinical Trials—a list

[Jaybee00]

From this paper Altmann et al. 2023
The immunology of long COVID

https://www.nature.com/articles/s41577-023-00904-7

https://www.s4me.info/threads/the-immunology-of-long-covid-2023-altmann-et-al.34116/

 

[Mij]

Immunoadsorption vs. Sham Treatment in Post COVID Patients With Chronic Fatigue Syndrome

https://classic.clinicaltrials.gov/ct2/show/NCT05954325?cond=ME/CFS&cntry=DE&sfpd_s=07/06/2023&sfpd_d=14&sel_rss=new14

 

[Jaybee00]

https://twitter.com/user/status/1697962998797631761


Dr. Scheibenbogen’s group at the Charité in Berlin has published interim results of a small open label study of repeat immunoadsorption (depletes immunoglobulin levels through apheresis). Of 10 post-Covid ME/CFS patients with elevated ß2-adrenergic AAbs, 7 responded to treatment

 

[Solstice]

https://twitter.com/user/status/1697962998797631761


Dr. Scheibenbogen’s group at the Charité in Berlin has published interim results of a small open label study of repeat immunoadsorption (depletes immunoglobulin levels through apheresis). Of 10 post-Covid ME/CFS patients with elevated ß2-adrenergic AAbs, 7 responded to treatment

Apheresis being the treatment where they pull your blood, take out what they don't like and put it back in again right?

 

[Jaybee00]

Yes

 

[Mij]

Dapagliflozin for Long Covid Syndrome (DALCO)

Study Overview
Brief Summary
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Detailed Description

This is a multi-centre, randomized, placebo-controlled trial (Figure 4). We will randomly assign patients with long COVID to 12 months of dapagliflozin 10 mg or placebo daily. The 10 mg daily dose of dapagliflozin was used in large clinical trials (44,48) and is the Health Canada approved dose for heart and kidney disease. Additionally, this dose was used in the MRI study of body composition (58) and the RCT in patients with acute COVID-19 (54).

Eligible patients with long COVID will be recruited from post COVID programs or advertisement through-multi-media. A total of 192 participants will be enrolled and this is anticipated to take 3 years. Participants will be followed for the entire duration of the study. Based on a study duration of 5 years (3-year recruitment, 2-year follow-up), patients will be followed for a median of 3.5 years.

 

[shak8]

Reduces volume load to heart by increasing glucose removed via kidneys/urine (diuretic effect). Classified as Type II diabetes med.
https://www.drugs.com/dapagliflozin.html

or my best amateur guess...